Hunan Er-Kang Pharmaceutical Co., Ltd.

Hunan Er-Kang Pharmaceutical Co., Ltd. faced a notable decline in stock performance, reaching an intraday low amid ongoing challenges. Despite a strong annual gain, recent financial metrics reveal profitability issues, including low return on capital employed and declining net sales, indicating increased risk in current trading conditions.

Hunan Er-Kang Pharmaceutical Co., Ltd. saw a notable rise in stock performance today, reaching an intraday high. The company has shown resilience in the short term, outperforming the broader market, but faces challenges such as low Return on Capital Employed and declining net sales over the past five years.

Hunan Er-Kang Pharmaceutical Co., Ltd. saw a significant intraday increase on March 24, 2026, contrasting with the broader market's performance. Despite a recent decline over the week and month, the company has achieved notable annual growth. However, it faces challenges with low profitability metrics and management efficiency.

Hunan Er-Kang Pharmaceutical Co., Ltd. faced a notable stock decline, dropping 6.7% today and 14.07% over the past week. The company has struggled with long-term growth, reflected in negative sales and profit trends, while its market capitalization is CNY 5,248 million within the pharmaceuticals sector.

Hunan Er-Kang Pharmaceutical Co., Ltd. faced a notable decline in its stock today, contrasting with the broader market's performance. The company has struggled with significant long-term financial challenges, including negative sales growth and a substantial drop in operating profit, reflecting ongoing profitability concerns in a tough market.

Hunan Er-Kang Pharmaceutical Co., Ltd. faced a notable stock decline, reaching an intraday low amid ongoing challenges. Despite a strong annual performance, the company has reported negative results for seven consecutive quarters, with significant declines in net sales and profitability, raising concerns about its long-term growth prospects.

Hunan Er-Kang Pharmaceutical Co., Ltd. saw significant stock activity today, rising notably despite a broader market decline. Over the past week, the company has shown strong gains, yet faces challenges with declining net sales and low return on capital, alongside a negative half-year profit. Its market capitalization is CNY 5,248 million.